Tigecycline, the first of a new class of broad-spectrum antibiotics (the glycylcyclines), has been licensed in South Africa for the parenteral treatment of adult patients with complicated intraabdominal infections (cIAIs) and complicated skin and soft-tissue infections (cSSTIs).
1
The guideline addressed important aspects of the new agent, including details of its metabolism and pharmacokinetics, mode of action, antibacterial spectrum, and performance in key clinical trials including data regarding its safety and tolerability, and also highlights appropriate use of the drug. Other aspects that were considered included breakpoints for susceptibility testing, in vitro and in vivo data for its activity against multi-drug resistant (MDR) pathogens such as carbapenem-resistant Acinetobacter baumannii, Enterobacteriaceae and Stenotrophomonas maltophilia, and its use in bacteraemic patients and Clostridium difficile infections (CDIs).
The guideline and its summary were written because of concern regarding the widespread misuse of antibiotics. The primary intention of the current publication is to facilitate, through a brief summary published in several professional journals, the heterogeneous use of antibiotics as a component of antibiotic stewardship. The emphasis is on clinical profiles that could potentially benefit from empiric or directed tigecycline therapy.
Appropriate use
Tigecycline has been studied as empiric monotherapy in cIAI, cSSTI and severe community-acquired pneumonia and would be an appropriate option as monotherapy for the treatment of patients with cIAI and cSSTI, which are the currently registered indications in South Africa, in the following circumstances: 
Empiric monotherapy

Directed combination therapy (based on culture results)
• In the absence of conclusive evidence, it is the authors' opinion that tigecycline may be effective as a salvage therapy for serious and life-threatening infections with MDR A. baumanii, if no other antibiotic is available according to susceptibility testing. In this scenario, combinations with polymyxin and/or fosfomycin and/or rifampicin may be appropriate. If used in this circumstance, unpublished pharmacokinetic/pharmacodynamic data suggest that it should be used at higher than the registered dose (at a dose of 100 -150 mg 12-hourly).
• Similarly, tigecycline may be used as salvage therapy on life-threatening S. maltophilia infections. In this scenario, standard dosing might be appropriate but consideration should be given to combination therapy with trimethoprim/sulphamethoxazole. • It is envisaged that tigecycline will be used in South Africa for directed therapy, particularly for carbapenem-resistant (ertapenem and/or imipenem-cilastatin and/or meropenem and/or doripenem) strains where, besides polymyxin and possibly fosfomycin, no alternative Gram-negative antibiotics are available. In this circumstance, tigecycline therapy should be combined with polymyxin in life-threatening infections.
Inappropriate use
Tigecycline is not an appropriate empiric option as monotherapy for the treatment of patients with cIAI at risk of infection with P. aeruginosa, and in particular in those with recurrent infection (tertiary peritonitis immuno-suppression and use of corticosteroid therapy. It is also not an appropriate empiric option as monotherapy for the treatment of patients with cSSTI where P. aeruginosa is a prevalent organism, such as in chronic diabetic foot infection and particularly in those patients with macerated, non-healing ulcers or wounds of long duration on prolonged broad-spectrum antibiotic therapy.
Conclusion
In summary, tigecycline would be an appropriate empiric option as monotherapy for the treatment of cIAIs and cSSSIs in patients when: Disclaimer. This statement is published for educational purposes only.
The recommendations are based on currently available scientific evidence together with the consensus opinion of the authors.
